MGI Saforis NDA To Be Based On Single Phase III Trial; Filing Planned For Q3

MGI Pharma expects to file an NDA for Saforis (l-glutamine oral suspension) for the treatment of oral mucositis based on the results of one Phase III trial and supportive earlier-phase trials